Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net (loss) income	$ (66,038)	$ 94,780	$ (674,780)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	381,927	365,334	382,783
Goodwill impairment	127,995	13,078	830,787
Equity-based compensation	21,876	14,880	22,468
Change in fair value of warrant liability	0	(4,021)	(34,482)
Reduction in the carrying amount of operating lease right-of-use assets	31,114	32,848	31,873
Reduction in the carrying amount of finance lease right-of-use assets	15,342	11,100	5,938
Deferred income tax expense (benefit)	47,163	32,049	(62,595)
Change in fair value of interest rate swaps, net of reclassification adjustment	0	(367)	(1,801)
Amortization of deferred financing costs	5,694	5,666	5,234
Loss on extinguishment of debt	0	2,273	0
Payment of contingent consideration from an acquisition	0	(1,850)	0
Gain on sale of businesses (note 4)	(32,602)	0	0
Other	2,721	2,128	350
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	30,986	(26,217)	(28,862)
Inventory	(11,491)	(28,065)	15,531
Prepaid and other assets	(61,071)	27,325	(20,305)
Operating lease obligations	(31,117)	(32,934)	(32,428)
Operating liabilities	139,272	33,832	40,955
Net cash provided by operating activities	601,771	541,839	480,666
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(382,388)	(306,055)	(337,463)
Payments for business acquisitions, net of cash acquired	(42,378)	(9,536)	(19,687)
Proceeds from the sale of businesses, net of cash disposed	120,420	0	0
Proceeds from the sale of assets	0	5,316	0
Payments for cost method investments	0	0	(128)
Receipt of contingent consideration from the sale of assets	1,156	0	0
Net cash used in investing activities	(303,190)	(310,275)	(357,278)
Cash flows from financing activities:
Repayments on long-term debt and lines of credit	(250,000)	(423,477)	(95,000)
Proceeds from borrowings on lines of credit	0	253,477	50,000
Repayments of finance lease obligations	(18,478)	(9,865)	(6,769)
Payments for shares purchased under share repurchase program	0	0	(29,275)
Proceeds from the exercise of stock options	0	742	587
Proceeds received in connection with employee stock purchase plan	1,211	999	2,031
Payments of debt financing costs	(25,045)	(1,432)	(3,224)
Payments of debt financing costs	0	(6,429)	0
Distributions to noncontrolling interests	(6,967)	(5,600)	(2,500)
Payments for tax withholdings from vesting of restricted stock units	(2,701)	(2,066)	(5,843)
Payments of contingent consideration and deferred purchase price from acquisitions	(212)	(5,298)	(2,535)
Net cash used in financing activities	(302,192)	(198,949)	(92,528)
Net (decrease) increase in cash	(3,611)	32,615	30,860
Cash at beginning of period	109,747	77,132	46,272
Cash at end of period	106,136	109,747	77,132
Supplemental disclosures:
Cash paid for interest	101,243	122,072	126,228
Cash paid for income taxes, net of refunds	24,283	14,139	14,756
Noncash investing and financing activities:
Unpaid equipment and other fixed asset purchases at end of period	65,892	56,123	35,867
Operating leases	37,872	35,871	22,000
Operating lease obligations	(37,872)	(35,871)	(22,000)
Write-off of assets subject to operating lease obligations	(2,605)	(6,653)	(14,675)
Write-off of operating lease obligations	2,605	6,653	14,675
Assets subject to finance lease obligations	31,392	17,871	32,101
Finance lease obligations	(31,392)	(17,871)	(32,101)
Write-off of assets subject to finance lease obligations	(1,552)	(513)	0
Write-off of finance lease obligations	1,552	513	0
Deferred purchase price in connection with acquisitions	$ 355	$ 0	$ 137